The Cardiovascular
Disease (CVD) therapy area encompasses a range of different diseases
and conditions affecting the heart and/or blood vessels. The most crucial risk
factors for CVD are hypertension and dyslipidemia, which accelerate the
development of atherosclerotic plaque build up within blood vessels. As
atheroma develops it causes the affected blood vessels to narrow, restricting
blood flow to the body, brain or heart, depending on its locale. It is also
possible for the fibrous cap of this plaque to break off, triggering the
coagulation cascade and causing a thrombus to form locally, which can
completely occlude blood flow.
The treatments of CVD typically focus on
prevention by controlling risk factors. As such, the treatments usually fall
within three categories: Anti-hypertensives, which aim to maintain blood
pressure within a normal range; anti-dyslipidemic drugs, which aim to modify
lipid levels to a normal range; and anti-thrombotic drugs, which aim to prevent
thrombi formation by inhibiting the coagulation cascade or platelet
aggregation. There has been vast scientific innovation in the CVD therapeutics
market in recent decades, particularly within the anti-dyslipidemia market.
This was seen first with the introduction of statins such as Lipitor
(atorvastatin) and more recently with the introduction of protein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors. However, other areas such as the
heart failure market remain poorly treated. Dyslipidemia and hypertension have
continuing high levels of development within the current pipeline and, despite
high levels of generic development, there is also a large degree of innovation,
with targets such as apolipoproteins and elements of the reverse lipid
transport pathway. In addition, the current pipeline includes nearly 200
products for the treatment of heart failure, suggesting an increase in interest
in treating the disease.
With over
1,400 products in active development, the pipeline for CVD is extensive. Does
current pipeline innovation hold the potential to change the CVD market in the
near future? The clinical trials process for CVD drugs is complex. What is the
risk of a CVD drug failing to reach the market? What is the risk of a drug
failing at a specific Phase? The CVD market landscape is forecast to undergo a
period of substantial change following key approvals, patent expiries and
acquisitions. Which of the leading companies will have the highest market share
by 2023? What strategies have these companies adopted to achieve market growth?
There has been a moderately high level of deal activity in recent years. How do
deal frequency and value compare between target families and molecule types? Understand
the current clinical and commercial landscape through a comprehensive analysis
of disease symptoms, diagnostic methods, etiology, pathophysiology, comorbidities
and complications, epidemiology, prognosis and treatment. Recognize the leading
therapeutics, as well as gaps in the market, with portfolios of key marketed
products, including historical and forecast sales revenue patterns. Identify
trends and developments, in terms of molecule type and molecular target, within
the overall CVD pipeline, as well as for key CVD indications: hypertension,
heart failure, dyslipidemia and thrombotic events. Consider market
opportunities and potential risks by examining trends in clinical trial
duration and size, as well as clinical trial failure rates, by stage of
development, key indication, molecule type and molecular target. Predict how
the evolving treatment landscape will drive market growth to 2023 and
understand the contributions that different products and companies will make to
this growth. Understand how strategic consolidations have shaped the current
pipeline and marketed products landscape.
Key
Topics Covered in the Report:-
Global Cardiovascular Disease Drugs Market Research Report
Global Cardiovascular Disease Drugs Market Forecast
Global Cardiovascular Disease Drugs Market Revenue
Global Cardiovascular Disease Drugs Market Size
Global Cardiovascular Disease Drugs Market Future Outlook
Global Cardiovascular Disease Drugs Market Analysis
Global Cardiovascular Disease Drugs Market Opportunities
Global Cardiovascular Disease Drugs Market Competition
Global Cardiovascular Disease Drugs Market Trends
Global Cardiovascular Disease Drugs Market Shares
Global Cardiovascular Disease Drugs Market Growth Analysis
Global Cardiovascular Disease Drugs Market
For more information on the research
report, refer to below link:- https://www.kenresearch.com/healthcare/pharmaceuticals/global-cardiovascular-disease-drugs-market-to-2023/142623-91.html
Related Reports by Ken Research:-
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-124 423 0204
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-124 423 0204
